Hyogo, Japan

Hiroko Tada

This inventor holds 3 USPTO granted patents. Top assignee: Takeda Chemical Industries, Inc.. Active years: 1992-1997.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hiroko Tada. Retrieved from https://idiyas.com/inventor/hiroko-tada-pwbfwqzn

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 2.9

ph-index = 2

Forward Citations = 28(Granted Patents)


Location History:

  • Hyogo, JP (1992)
  • Kawanishi, JP (1992)
  • Okayama, JP (1997)

Company Filing History:


Years Active: 1992-1997

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Hiroko Tada: Innovator in Biotechnology

Introduction

Hiroko Tada is a prominent inventor based in Hyogo, Japan. She has made significant contributions to the field of biotechnology, particularly in the development of recombinant DNA technologies. With a total of 3 patents to her name, Tada's work has the potential to impact medical treatments and therapeutic applications.

Latest Patents

Tada's latest patents include groundbreaking innovations such as an antibody-encoding recombinant DNA and its use. This invention involves transforming a bacterium of the genus Bacillus by introducing a vector that incorporates DNA encoding an antibody. The resulting transformant is cultivated in a medium to produce and accumulate the antibody in an active form in the culture liquid. This method allows for the easy production of recombinant antibodies in large amounts, thanks to successful secretory expression using Bacillus.

Another notable patent is related to recombinant human lymphotoxins that possess an N-terminal extended linker. This invention discloses a novel recombinant human lymphotoxin mutein that combines with an antibody at an inactive site of the LT molecule. It liberates the LT molecule easily from the antibody after incorporation into tumor cells. The recombinant human LT mutein is prepared by introducing a polydeoxyribonucleic acid containing a nucleotide sequence coding for a specific amino acid sequence into a replicable vector. This innovation is useful for tumor-selective carcinostatics and enhances the activity of LT while reducing its side effects.

Career Highlights

Hiroko Tada is currently associated with Takeda Chemical Industries, Inc., where she continues to advance her research and development efforts. Her work has garnered attention in the scientific community, and she is recognized for her innovative approaches to biotechnology.

Collaborations

Tada has collaborated with notable colleagues such as Susumu Iwasa and Yukio Toyoda. These partnerships have contributed to her success and the advancement of her research projects.

Conclusion

Hiroko Tada is a trailblazer in the field of biotechnology, with her innovative patents paving the way for advancements in medical treatments. Her contributions are significant and continue to influence the industry positively.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…